About Admin

This author has not yet filled in any details.
So far Admin has created 73 blog entries.

Biovica presents at Unicorn Summit 2017

Anders Rylander, CEO will present at the Vator Securities Unicorn Summit in Stockholm on March 7, 2017. The presentation, part of the company’s planned IPO on Nasdaq First North in March 2017, is intended for investors. The purpose of the IPO is to raise funds to initiate the commercialization phase of the company’s DiviTum™ [...]

February 23rd, 2017 15:00|News|

Biovica strengthens its management

Uppsala, Sweden, February 20, 2017. Biovica has strengthened its management team to ensure continued successful development. Cecilia Driving (CFO), Karin Mattsson (R&D Director) and Johanna Faris (Quality and Regulatory Assurance Director) have joined the company.

February 22nd, 2017 13:30|News|

Biovica stärker bolagsledningen

Uppsala, 20 februari, 2017. Biovica har stärkt bolagets ledningsgrupp för att säkerställa en fortsatt framgångsrik utveckling av bolaget. Bolaget har förstärkts med Cecilia Driving (CFO),  Karin Mattsson (FoU Chef) och Johanna Faris (Regulatory och Kvalitetschef). Cecilia Driving har dubbla examen inom Ekonomi och Juridik, samt har haft flera CFO positioner inom life-science, private [...]

February 22nd, 2017 08:30|Press Release|

Nya resultat för DiviTum™ som effektmarkör för CDK4/6 hämmare presenteras på AACR

Uppsala, Sverige, 16 februari, 2017. Den årliga konferensen för American Association for Cancer Research (AACR) den 1-5 april är en av de största vetenskapliga konferenserna för cancerforskare och onkologer. Tillsammans med Dana Farber Cancer Institute och Karolinska Institutet kommer Biovica att presentera nya data på DiviTum™-teknologin som effektmarkör för CDK4/6-hämmare. "På AACR kommer vi [...]

February 16th, 2017 11:30|News|

New data on DiviTum will be presented at AACR

Uppsala, Sweden, February 16, 2017. The American Association for Cancer Research (AACR) Annual Meeting on April 1-5 will gather the world’s leading cancer researchers and oncologists. Together with its research partners Dana Farber Cancer Institute and the Karolinska Institute, Biovica will present new data on the company’s DiviTum™ assay as a response marker for CDK4/6 [...]

February 16th, 2017 11:30|News|

Kallelse till extra bolagsstämma i Biovica International AB

Kallelse till extra bolagsstämma i Biovica International AB Styrelsen i Biovica International AB, org.nr 556774-6150, kallar härmed till extra bolagsstämma. Datum: 2 mars 2017 Tid: 16:00 Plats: Dag Hammarskjölds väg 54B i Uppsala Anmälan/rätt att delta på stämman Aktieägare som vill delta i bolagsstämman ska vara införd i den av Euroclear Sweden AB förda [...]

February 7th, 2017 17:09|Press Release|

Biovica interviewed about the upcoming IPO

Anders Rylander, CEO of Biovica and Mattias Bergqvist, VP Marketing & Clinical Development discuss the challenges in cancer diagnostics, go-to-market strategies, clinical results and IPO preparations in the latest edition of Vatorpodden. The interview is available in Swedish (only)

February 3rd, 2017 14:56|News|

Biovica discuss the latest clinical results in Vatorpodden

Listen to Anders Rylander, CEO of Biovica and Mattias Bergqvist VP Sales & Marketing being interviewed in the latest edition of Vatorpodden. Anders and Mattias discuss the latest clinical results presented at the 2016 San Antonio Breast Cancer Symposium. The interview is available in Swedish (only)

January 2nd, 2017 15:00|News|

Kallelse till extra bolagsstämma

Kallelse till extra bolagsstämma i Biovica International AB Styrelsen i Biovica International AB, org.nr 556774-6150, kallar härmed till extra bolagsstämma. Datum:          24 januari 2017 Tid:                16:00 Plats:             Nybrokajen 7, 6 tr, Stockholm Anmälan/rätt att delta på stämman Aktieägare som vill delta i bolagsstämman skall vara införd i den av Euroclear Sweden AB förda aktieboken [...]

December 21st, 2016 13:00|Press Release|

Unique results demonstrate DiviTum™ capabilities

Unique results show DiviTum™ is able to evaluate the anti-tumor activity of blockbuster cancer drug [Uppsala, Sweden, December 12, 2016] - New clinical study results presented at the San Antonio Breast Cancer Symposium, the world’s leading breast cancer conference, 6-10 December 2016, demonstrate that Biovica’s DiviTum™ biomarker assay can evaluate the efficacy of [...]

December 12th, 2016 08:30|Press Release|